What It Takes — Central Nervous System (Cns) Clinical Trials
The central nervous system (CNS) is a vital part of the nervous system that consists the brain and the spinal cord. It integrates the received information, thereafter coordinating and controlling the activities of all parts of the body. However, CNS disorders such as neurodegenerative diseases, autoimmune & inflammatory diseases, genetic disorders, cancers, and others affect the structure and function of the brain or spinal cord. Thus, CNS therapeutics are used to treat these disorders.
The World Health Organization and the American Association of Neurological Surgeons conduct various seminars to increase awareness about psychological disorders and their treatments. In addition, these organizations have helped to create groups in which patients can interact with each other as well as with the professionals and can have a holistic approach toward healing, which drives the market growth.
Download PDF Brochure of study, Click Here
Biopharmaceutical companies developing new CNS products can face special obstacles. According to an article published on National Center for Biotechnology Information, “despite great advances in basic neuroscience knowledge, the improved understanding of brain functioning has not yet led to the introduction of truly novel pharmacological approaches for the treatment of central nervous system disorders. This situation has been partly attributed to the difficulty of predicting efficacy in patients based on results from preclinical studies.” Hence why clinical pharmacology trials for CNS drugs are complex and require in-depth clinical expertise.
There are many CNS depressants, and most act on the brain similarly they affect the neurotransmitter gamma-aminobutyric acid (GABA). Neurotransmitters are brain chemicals that facilitate communication between brain cells. GABA works by decreasing brain activity. Although different classes of CNS depressants work in unique ways, ultimately it is their ability to increase GABA activity that produces a drowsy or calming effect. Despite these beneficial effects for people suffering from anxiety or sleep disorders, barbiturates and benzodiazepines can be addictive and should be used only as prescribed.
CNS diseases range from depression, Alzheimer’s, ADHD, social phobia, to pain. The ability to recruit the right patient populations is especially important in studies involving CNS-acting drugs due to safety concerns and the potential to look at proof of concept early in development.
This report provides a comprehensive analysis and profiles of major players such as Pfizer, Inc., Biogen, Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, Inc., Merck & Co., Inc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Shire Plc, and Allergan Plc. The other players in the value chain include Cipla Limited, GlaxoSmithKline plc, Lupin Limited, Otsuka Pharmaceutical Co., Ltd., Lundbeck, and others.
Source: The Insight Partners